
News|Articles|June 25, 2025
Three-year outcomes of aflibercept 8mg in neovascular age related macular degeneration and diabetic macular edema
Author(s)Sponsored by Bayer
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement






























